AI Article Synopsis
- Azithromycin gained attention for its potential use against COVID-19, despite being primarily known for its antimicrobial properties.
- Initial promising results for COVID-19 treatment have been overshadowed by insufficient scientific evidence supporting its effectiveness as an antiviral.
- The review aims to assess whether azithromycin should continue to be considered as a COVID-19 treatment or if it should be used only for its established antimicrobial and immunomodulatory roles, to avoid contributing to antibiotic resistance.
Article Abstract
Azithromycin has become famous in the last two years, not for its main antimicrobial effect, but for its potential use as a therapeutic agent for COVID-19 infection. Initially, there were some promising results that supported its use, but it has become clear that scientific results are insufficient to support such a positive assessment. In this review we will present all the literature data concerning the activity of azithromycin as an antimicrobial, an anti-inflammatory, or an antivirus agent. Our aim is to conclude whether its selection should remain as a valuable antivirus agent or if its use simply has an indirect therapeutic contribution due to its antimicrobial and/or immunomodulatory activity, and therefore, if its further use for COVID-19 treatment should be interrupted. This halt will prevent further antibiotic resistance expansion and will keep azithromycin as a valuable anti-infective therapeutic agent.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9404997 | PMC |
| http://dx.doi.org/10.3390/antibiotics11081063 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!